Betting on Demographics, SWFs Plunge into Health Care

February 02, 2015 by Loch Adamson

  • Print
  • Please login
Target Regions of SWF Direct Healthcare Investment, 2005-’15 (Number and Total) It was a huge day for Juno Therapeutics, a fledgling, Seattle-based biotechnology company. On December 19, amid raucous applause and a blizzard of confetti at the Nasdaq Stock Market’s MarketSite studio, overlooking New York’s Times Square, the company made its trading debut. Juno, which develops gene therapies that activate a patient’s own immune system cells to attack tumors, had priced its initial public offering at $24, and shares closed the day at $35, making it one of the hottest IPOs of the year. Though CEO Hans Bishop was on hand for the festivities, he wasn’t the biggest winner. Nor were Juno’s underwriters or even the prestigious medical institutions, including Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center, that own big stakes of the company. Instead, the $51 billion Alaska Permanent Fund, holding 34.75 percent…

Sign-up for your free account to read this article

Get Started

Already have an account?
 

Log In Here

Updated Fund Profiles

Our market-leading fund profile library provides unrivalled analysis of more than 90 government and sovereign funds.

Register to read fund profiles

Recent SWF Investments

Search the database of direct investments and mandates by fund, industry and target market to identify past deals that match your requirements. Access over $1 trillion worth of transactions dating back to the 1960s.

Register to explore our data

Latest SWF News

Sovereign Wealth Center makes staying abreast of the most recent government and sovereign fund events easy. Our team undertakes a thorough review of global news feeds every morning and distills salient points.

Register for the latest SWF news
Join the discussion:

To be able to print this content,
you must be a subscriber

For details on your subscription options,
please contact: